(Q37698761)

22 August 2017

1 reference

title

Reducing empiricism in malaria vaccine design (English)

1 reference

22 August 2017

0 references

1 reference

1 reference

2

Marie Paule Kieny

1 reference

22 August 2017

Vasee S Moorthy

1

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Lancet Infectious Diseases

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

204-211

1 reference

Measuring malaria endemicity from intense to interrupted transmission

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

The economic and social burden of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

The past, present and future of childhood malaria mortality in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A multilateral effort to develop DNA vaccines against falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

The development of the RTS,S malaria vaccine candidate: challenges and lessons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Protection against a malaria challenge by sporozoite inoculation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

The complexity of protective immunity against liver-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Aotus monkeys: their great value for anti-malaria vaccines and drug testing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Cytokine responses during acute simian Plasmodium cynomolgi and Plasmodium knowlesi infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

The importance of human FcgammaRI in mediating protection to malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Vaccines: correlates of vaccine-induced immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

A framework for assessing immunological correlates of protection in vaccine trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Pre-erythrocytic malaria vaccines: towards greater efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970329-9

7 January 2021

10.1016/S1473-3099(09)70329-9

Identifiers

DOI

1 reference

22 August 2017

1 reference